Mixed results in palonosetron, granisetron head-to-head trial

The findings of a phase III trial pitting a second- against a first-generation 5-hydroxytryptamine 3 receptor antagonist suggest that choosing the appropriate 5-HT3 inhibitor as part of a triplet regimen to prevent chemotherapy-induced nausea and vomiting may not be straightforward.
Source: MedWire News - Category: Consumer Health News Tags: Oncology Source Type: news